$1.01
+0.07 (+7.41%)
Open$0.97
Previous Close$0.94
Day High$1.02
Day Low$0.96
52W High$2.57
52W Low$0.88
Volume—
Avg Volume571.8K
Market Cap58.61M
P/E Ratio—
EPS$-1.00
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,027.7% upside
Current
$1.01
$1.01
Target
$11.39
$11.39
$7.11
$11.39 avg
$14.81
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.72M | 5.17M | 16.16M |
| Net Income | -59,284,581 | -58,402,060 | -2,032,977 |
| Profit Margin | -1,256.8% | -1,194.0% | -12.6% |
| EBITDA | -60,737,199 | -63,157,113 | -2,828,117 |
| Free Cash Flow | — | — | -1,769,464 |
| Rev Growth | -8.6% | -8.6% | -2.0% |
| Debt/Equity | 0.26 | 0.26 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |